RBC Capital analyst Gregory Renza maintains Amgen (NASDAQ:AMGN) with a Outperform and raises the price target from $328 to $332.
RBC Capital Maintains Outperform on Amgen, Raises Price Target to $332
The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.